Pharma and regulators want safety, consistency, and oversight
However, 7 cross sectional studies examining acute effects of the GLP-1-based therapies 37,38,39,40,41,42,43 found a significant increase in % FMD following GLP-1-based interventions (mean difference in the changes from baseline: 2.58 [1.68, 3.53] %
Interestingly, emerging evidence suggests that GLP-1RAs may also provide therapeutic behavioral modification beyond their effects on appetite and food preferences
Maintain 7-9 hours of quality sleep, manage stress, exercise moderately, and avoid close contact with sick individuals when possible
If the drug protected the heart only by shrinking the waistline, the benefit would track the weight